Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 212

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 212
---
convenience, the trademarks and trade names in this registration statement are referred to without the and symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest
extent under applicable law, their rights thereto. We do not intend our use or display of other companies’ trademarks and trade
names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Facilities

We have an operating lease
for laboratory in Hong Kong, with 2,021 square feet lab space under a lease that commenced in March 2020, renewed in March 2023 and expires
in March 2026. The monthly rent ranges from $6,348 to $9,068. Payments under operating leases are expensed on a straight-line basis over
the periods of the respective leases, and the terms of the leases do not contain contingent rent and renewal or purchase options.

We believe our current facilities
are sufficient to meet our needs.

Legal Proceedings

On December 16, 2024, the
Company received a letter from Carey Olsen with a Summons with Notice dated September 3, 2024, taken out by Karen Cheung (a/k/a Wing TSZ
Cheung) as plaintiff against, among others, the Company as defendant in the Supreme Court of the State of New York County of New York,
in relation to an action to recover financial losses sustained by the plaintiff (the “Case”). The Case is at the very early
stages of litigation and although we intend to defend the lawsuit, there can be no assurance regarding the ultimate outcome of this case.
Due to the inherent uncertain nature of litigation, the ultimate outcome or actual cost of settlement may materially vary from estimates.
If management’s estimates prove incorrect, current reserves could be inadequate and we could incur a charge to earnings which could
have a material adverse effect on our results of operations, financial condition, net worth, and cash flows.

Regulations

Government authorities in
the United States at the federal, state and local level and in other countries extensively regulate, among other things, the research
and clinical development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising,
distribution, post-approval monitoring and reporting, marketing, pricing, export and import of drug products (“Regulated Products”),
such as those we are developing. Generally, before a new Regulated Product can be marketed, considerable data demonstrating its quality,
safety